Current posture

What matters now

Sangamo is in an asset-sale chapter 11, with the proposed stalking-horse sale currently facing limited objections from Astellas and Alexion over a sale free and clear of encumbrances. Astellas limited objection Dkt. 307 Alexion limited objection Dkt. 309 An emergency hearing is scheduled for August 28, 2026, with the sale-related disputes and the path to closing the immediate issues to watch. The genomic-medicine company filed its voluntary Chapter 11 petition Dkt. 1 on June 23, 2026 after sustained operating losses, a steep fall in collaboration revenue, and a weaker biotech-financing market; its first-day declaration says the company entered the case with no funded debt. First-day declaration Dkt. 2 The filing was designed to run a section 363 process rather than a standalone balance-sheet restructuring: Sangamo identified stalking-horse transactions for its Fabry program and neurological technology-platform assets, while obtaining debtor-in-possession liquidity to preserve operations through the process. Petition and sale strategy Dkt. 1 First-day declaration Dkt. 2 The case has since shifted from marketing assets to resolving the terms on which those assets can be sold. The August objections indicate that…

Updated Aug 26, 2026